References
- Danielsson G, Malmstrom PU, Jahnson S, et al. Bladder health in patients treated with BCG instillations for T1G2-G3 bladder cancer - a follow-up five years after the start of treatment. Scand J Urol. 2018;52:377–384.
- Brausi M, Oddens J, Sylvester R, et al. Side effects of Bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 2014;65:69–76.
- Krajewski W, Matuszewski M, Poletajew S, et al. Are there differences in toxicity and efficacy between various bacillus calmette-guerin strains in bladder cancer patients? Analysis of 844 patients. Urol Int. 2018;101:277–284.